MyMedR

Displaying all 2 publications

Abstract:

Sort:

Fulltext Clinical outcomes of dogs with high-grade cutaneous mast cell tumors

Ong SM, McKenna C, Pinard C, Richardson D, Oblak ML

Front Vet Sci, 2024;11:1519636.
PMID: 39906044 DOI: 10.3389/fvets.2024.1519636

OBJECTIVES: To evaluate the prognostic factors and treatment outcomes in dogs with high-grade cutaneous mast cell tumors (HGMCTs).
METHODS: Medical records of dogs with a histopathologic diagnosis of HGMCTs were reviewed from a single institution. Clinical factors, treatment-related variables, and adjuvant therapies were documented to evaluate their association with clinical outcomes. Comparative and survival analyses were conducted using Kaplan-Meier survival analysis, log-rank, and Fisher's exact tests.
RESULTS: The overall median survival time for the 77 dogs was 317 days (range 20-3,041 days) with 6-month, 1-year, and 2-year survival rates of 69, 50, and 30%, respectively. Surgically treated dogs had significantly prolonged survival and were 6.88 times more likely to survive beyond 5.5 months. The presence of metastasis at initial staging was strongly associated with poorer outcomes, as dogs without metastasis at initial staging had 6.94 times higher odds of surviving beyond 2 years. Surgical sites with incomplete margins had a higher local recurrence rate (58%) compared to those with clean margins (26%). Despite aggressive treatment, 75% of the dogs that received concurrent surgical and adjuvant therapy experienced disease progression. Lymph node extirpation, tumor localization, number of tumors, and local recurrence were not associated with the overall outcome.
CLINICAL RELEVANCE: The combination of aggressive local therapy and adjuvant systemic chemotherapy provides a notable survival benefit in dogs with HGMCTs. The limited therapeutic benefit of locoregional lymph node extirpation, combined with a persistently high metastatic rate despite systemic chemotherapy, highlights the critical need for more effective regional and systemic treatment approaches for HGMCT patients.
Fulltext Comparison of the ABC and ACMG systems for variant classification

Houge G, Bratland E, Aukrust I, Tveten K, Žukauskaitė G, Sansovic I, et al.

Eur J Hum Genet, 2024 Jul;32(7):858-863.
PMID: 38778080 DOI: 10.1038/s41431-024-01617-8

The ABC and ACMG variant classification systems were compared by asking mainly European clinical laboratories to classify variants in 10 challenging cases using both systems, and to state if the variant in question would be reported as a relevant result or not as a measure of clinical utility. In contrast to the ABC system, the ACMG system was not made to guide variant reporting but to determine the likelihood of pathogenicity. Nevertheless, this comparison is justified since the ACMG class determines variant reporting in many laboratories. Forty-three laboratories participated in the survey. In seven cases, the classification system used did not influence the reporting likelihood when variants labeled as "maybe report" after ACMG-based classification were included. In three cases of population frequent but disease-associated variants, there was a difference in favor of reporting after ABC classification. A possible reason is that ABC step C (standard variant comments) allows a variant to be reported in one clinical setting but not another, e.g., based on Bayesian-based likelihood calculation of clinical relevance. Finally, the selection of ACMG criteria was compared between 36 laboratories. When excluding criteria used by less than four laboratories (<10%), the average concordance rate was 46%. Taken together, ABC-based classification is more clear-cut than ACMG-based classification since molecular and clinical information is handled separately, and variant reporting can be adapted to the clinical question and phenotype. Furthermore, variants do not get a clinically inappropriate label, like pathogenic when not pathogenic in a clinical context, or variant of unknown significance when the significance is known.

Filters

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links